Response to "No increased risk of breast or gynecologic malignancies in women exposed to spironolactone for dermatologic conditions: A retrospective cohort study"

J Am Acad Dermatol. 2024 Dec;91(6):e171-e172. doi: 10.1016/j.jaad.2024.05.105. Epub 2024 Aug 20.

¹ University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; The Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, New York, New York. Electronic address: [email protected].
² The Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, New York, New York; New York Medical College, Valhalla, New York.
³ The Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, New York, New York.

No abstract available

Keywords: breast cancer; malignancy; risk assessment; spironolactone.

Publication types